YS Biopharma Holds EGM, Approves All Resolutions
Ticker: LSBWF · Form: 6-K · Filed: May 21, 2024 · CIK: 1946399
| Field | Detail |
|---|---|
| Company | Ys Biopharma CO., LTD. (LSBWF) |
| Form Type | 6-K |
| Filed Date | May 21, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-meeting, results
TL;DR
YS Biopharma EGM passed all votes, directors elected, auditors appointed. All clear for now.
AI Summary
YS Biopharma Co., Ltd. announced the results of its Extraordinary General Meeting held on May 21, 2024. Shareholders approved all proposed resolutions, including the election of directors and the appointment of auditors. The company, formerly known as YishengBio Co., Ltd., is based in Beijing, PRC.
Why It Matters
The successful conclusion of the Extraordinary General Meeting and approval of resolutions are crucial for the company's ongoing governance and operational continuity.
Risk Assessment
Risk Level: low — This filing is a routine report of an EGM's results and does not introduce new financial or operational risks.
Key Players & Entities
- YS Biopharma Co., Ltd. (company) — Registrant
- YishengBio Co., Ltd. (company) — Former company name
- May 21, 2024 (date) — Date of Extraordinary General Meeting
- Beijing, PRC (location) — Company headquarters
FAQ
What was the primary purpose of the Extraordinary General Meeting?
The primary purpose was to announce the results of the Extraordinary General Meeting held on May 21, 2024, where shareholders approved all proposed resolutions.
When was the Extraordinary General Meeting held?
The Extraordinary General Meeting was held on May 21, 2024.
What key decisions were made at the EGM?
Shareholders approved all proposed resolutions, including the election of directors and the appointment of auditors.
What was YS Biopharma Co., Ltd.'s former name?
YS Biopharma Co., Ltd.'s former name was YishengBio Co., Ltd.
Where is YS Biopharma Co., Ltd. located?
YS Biopharma Co., Ltd. is located in Beijing, PRC.
Filing Stats: 171 words · 1 min read · ~1 pages · Grade level 9.7 · Accepted 2024-05-21 16:30:08
Filing Documents
- ea0206615-6k_ysbio.htm (6-K) — 9KB
- ea020661501ex99-1_ysbio.htm (EX-99.1) — 8KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-24-045611.txt ( ) — 22KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission file number: 001-41598 YS BIOPHARMA CO., LTD. (Exact name of registrant as specified in its charter) Building No. 2, 38 Yongda Road Daxing Biomedical Industry Park Daxing District, Beijing, PRC Tel: 010-89202086 (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F EXHIBITS Exhibit No. Description 99.1 Press Release – YS Biopharma Announces Results of Extraordinary General Meeting 1 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. YS Biopharma Co., Ltd. By: /s/ Hui Shao Name: Hui Shao Title: Director and Co-Chief Executive Officer Date: May 21, 2024 2